Jim Cramer Predicts Trillion-Dollar Market Cap for Eli Lilly Amid Weight-Loss Drug Boom
CNBC's Jim Cramer has doubled down on his bullish stance for Eli Lilly (LLY), forecasting the pharmaceutical giant could reach a trillion-dollar valuation. The 'Mad Money' host cites Zepbound, the company's blockbuster weight-loss drug, as the primary catalyst alongside a robust pipeline of cancer treatments and other therapies.
Eli Lilly's current $754 billion market cap leaves significant upside for investors betting on the obesity drug market's expansion. Cramer's endorsement reflects broader Wall Street optimism, with analysts viewing Lilly's development of a weight-loss pill as a potential industry gamechanger.